Browse > Article

Acute Respiratory Failure Developed in Non-small Cell Lung Cancer Patients Treated With Gefitinib  

Ryu, Jeong-Seon (Department of Internal Medicine, College of Medicine, Inha University)
Kim, Lucia (Department of Pathology, College of Medicine, Inha University)
Kim, Chul-Hyun (Department of Internal Medicine, College of Medicine, Inha University)
Kim, Hyun-Jung (Department of Internal Medicine, College of Medicine, Inha University)
Cho, Jae-Hwa (Department of Internal Medicine, College of Medicine, Inha University)
Kwak, Seung-Min (Department of Internal Medicine, College of Medicine, Inha University)
Lee, Hong-Lyeol (Department of Internal Medicine, College of Medicine, Inha University)
Publication Information
Tuberculosis and Respiratory Diseases / v.62, no.2, 2007 , pp. 144-148 More about this Journal
Abstract
Gefitinib is an oral selective inhibitor that targets the tyrosine kinase of the epidermal growth factor receptor. The prevalence of interstitial lung disease is 2% in Japan and 0.3% in the USA with a mortality rate of up to one third. We describe two non-small cell lung cancer patients who developed acute respiratory failure after gefitinib, and suggest that clinicians take extreme caution when deciding to treat patients with gefitinib.
Keywords
Adverse effect; Gefitinib; Lung cancer;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, et al. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-56   DOI   ScienceOn
2 Okamoto I, Fujii K, Matsumoto M, Terasaki Y, Kihara N, Kohrogi H, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 2003;40:339-42   DOI   ScienceOn
3 Inomata S, Takahashi H, Nagata M, Yamada G, Shiratori M, Tanaka H, et al. Acute lung injury as an adverse event of gefitinib. Anticancer Drugs 2004;15:461-7   DOI   ScienceOn
4 Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 2006;174:550-6   DOI   ScienceOn
5 Sumpter K, Harper-Wynne C, O'Brien M, Congleton J. Severe acute interstitial pneumonia and gefitinib. Lung Cancer 2004;43:367-8   DOI   ScienceOn
6 Rabinowits G, Herchenhorn D, Rabinowits M, Weatge D, Torres W. Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine. Anticancer Drugs 2003;14:665-8   DOI   ScienceOn
7 Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-9
8 Fujiwara Y, Kiura K, Toyooka S, Takigawa N, Tokumo M, Hotta K, et al. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer. Lung Cancer 2006;52:99-103   DOI   ScienceOn
9 Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, et al. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-9   DOI   ScienceOn
10 Nagaria NC, Cogswell J, Choe JK, Kasimis B. Side effects and good effects from new chemotherapeutic agents: case 1. Gefitinib-induced interstitial fibrosis. J Clin Oncol 2005;23:2423-4   DOI   ScienceOn
11 Ieki R, Saitoh E, Shibuya M. Acute lung injury as a possible adverse drug reaction related to gefitinib. Eur Respir J 2003;22:179-81   DOI   ScienceOn
12 Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104   DOI   ScienceOn
13 Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-8   DOI   ScienceOn
14 Seto T, Seki N, Uematsu K, Tanigaki T, Shioya S, Koboyashi T, et al. Gefitinib-induced lung injury successfully treated with high-dose corticosteroids. Respirology 2006;11:113-6   DOI   ScienceOn
15 Ohyanagi F, Ando Y, Nagashima F, Narabayashi M, Sasaki Y. Acute gefitinib-induced pneumonitis. Int J Clin Oncol 2004;9:406-9   DOI   ScienceOn